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A B S T R A C T
In primary aldosteronism (PA) the differentiation of unilateral aldosterone-producing adenomas (APA) from
bilateral adrenal hyperplasia (BAH) is usually performed by adrenal venous sampling (AVS) and/or computed
tomography (CT). CT alone often lacks the sensitivity to identify micro-APAs. Our objectives were to establish if
steroid profiling could be useful for the identification of patients with micro-APAs and for the development of an
online tool to differentiate micro-APAs, macro-APAs and BAH. The study included patients with PA (n=197)
from Munich (n=124) and Torino (n=73) and comprised 33 patients with micro-APAs, 95 with macro-APAs,
and 69 with BAH. Subtype differentiation was by AVS, and micro- and macro-APAs were selected according to
pathology reports. Steroid concentrations in peripheral venous plasma were measured by liquid chromato-
graphy-tandem mass spectrometry. An online tool using a random forest model was built for the classification of
micro-APA, macro-APA and BAH. Micro-APA were classified with low specificity (33%) but macro-APA and BAH
were correctly classified with high specificity (93%). Improved classification of micro-APAs was achieved using a
diagnostic algorithm integrating steroid profiling, CT scanning and AVS procedures limited to patients with
discordant steroid and CT results. This would have increased the correct classification of micro-APAs to 68% and
improved the overall classification to 92%. Such an approach could be useful to select patients with CT-un-
detectable micro-APAs in whom AVS should be considered mandatory.
1. Introduction
Primary aldosteronism (PA) is the most frequent form of endocrine
hypertension characterized by aldosterone overproduction relative to
suppressed plasma renin [1–3]. Patients with PA have an increased risk
of cardiovascular and cerebrovascular events and renal disease
progression relative to patients with primary hypertension including
those with similar cardiovascular risk profiles [4–7]. This highlights the
importance of early diagnosis and appropriate clinical management to
minimize detrimental cardiovascular outcomes.
Unilateral PA is mainly caused by an aldosterone-producing ade-
noma (APA) and is potentially curable by laparoscopic unilateral
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adrenalectomy whereas bilateral PA (bilateral adrenal hyperplasia
[BAH]) is usually treated with a mineralocorticoid receptor antagonist
(MRA). These specific treatment options emphasize the central role of
an accurate differentiation of APA from BAH in the diagnostic work up
of PA which is usually performed by computed tomography (CT) and
adrenal venous sampling (AVS) [8]. The sensitivity of CT imaging is
often insufficient for the identification of APAs less than 10mm in
diameter, while AVS displays high sensitivity and specificity (95% and
100%, respectively) to distinguish unilateral from bilateral PA [9,10].
AVS is a technically-demanding and invasive procedure with non-
standardized protocols and variable interpretation of results, and al-
ternative approaches to reduce or even replace AVS for subtype dif-
ferentiation in PA are currently sought [11–16].
Various definitions of size of micro-APAs have been used which
usually consider the CT-undetectable feature [9,17–20]. Micro-APAs
have been classified as< 10mm in diameter, although in certain cir-
cumstances, ie, localization in an expanded adrenal limb, micro-APAs
of 6mm in diameter have been detected by CT [17]. CYP11B2 (aldos-
terone synthase) expression per tumour area by immunohistochemistry
has been reported as higher in micro-APAs compared with macro-APAs
together with a higher reported capacity for aldosterone production per
tumour area [21]. CT-undetectable micro-APAs have a reported pre-
valence of 13%–30% in patients with APAs [9,17–20] and therefore
comprise a significant proportion of patients with APAs with potentially
distinctive adrenal steroid profiles and clinical outcomes.
In the present study, we determined the liquid chromatography-
tandem mass spectrometry (LC–MS/MS)-based steroid profiles of
peripheral venous plasma samples from patients with micro-APAs
(< 10mm in diameter), macro-APAs (≥10mm in diameter) and BAH.
Our objectives were to establish if steroid profiling could be useful to
select patients with micro-APAs in whom AVS should be considered
mandatory and determine if a diagnostic algorithm that integrates
steroid profiling could help rationalize the use of AVS procedures in
patients with PA.
2. Subjects and methods
The subjects included in this study were 197 patients diagnosed
with PA from two referral centers (124 patients from Medizinische
Klinik IV, Klinikum der Ludwig-Maximilians-Universität München,
Munich, Germany and 73 patients from Division of Internal Medicine
and Hypertension, University of Turin, Turin, Italy). The study was
approved by the appropriate institutional ethics committees and
written informed consent was obtained from all patients.
2.1. Diagnosis and treatment
PA was diagnosed in both Munich and Torino in accordance with
the Endocrine Society Clinical Guideline using the aldosterone-to-renin
ratio (ARR) as a screening test, confirmatory testing by saline infusion
testing and subtype differentiation by AVS. Detailed methods for the
diagnosis of PA and AVS procedures are described elsewhere [10,22].
In all patients, AVS procedures were performed under basal conditions
and successful catheterization was defined with a selectivity index
Fig. 1. CYP11B2 immunohistochemistry micro-
APA and macro-APA.
The histopathology of resected adrenals from
patients with a micro-APA (Panels A, B, C and
D) or a macro-APA (Panels E and F) are shown
with hematoxylin and eosin (H&E) staining
(Panels A, C and E) and CYP11B2 im-
munostaining (Panels B, D and F). Micro-APAs
in this study were classfied as a single micro-
APA (diameter< 10mm, as indicated by a
single arrow in panel B) or the largest CYP11B2
positive nodule (with diameter< 10mm, as
indicated by a single arrow in panel D) in an
adrenal with more than one nodule with
CYP11B2 immunostaining. An example of a
macro-APA is indicated with a double arrow in
panel F. Scale bar= 2mm. CYP11B2, aldos-
terone synthase; H&E, hematoxylin and eosin.
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(adrenal vein to peripheral cortisol ratio) ≥2.0. Unilateral PA was
defined by a lateralization ratio (dominant to contralateral aldosterone-
to-cortisol concentration ratio) ≥4.0.
2.2. Classification of micro-APAs and macro-APAs and assessment of
postoperative outcomes
Pathology reports were used for an assessment of the diameter of
the largest nodule in resected adrenals for an initial classification of
adenomas as micro-APAs or macro-APAs. Macro-APAs were defined by
the largest nodule diameter ≥10mm from pathology reports alone.
Micro-APAs, from the initial assessment from pathology reports, were
then analysed by CYP11B2 immunohistochemistry [23] and this group
included either a single microadenoma with CYP11B2 immunostaining
(diameter< 10mm) or the largest nodule (with diameter< 10mm) in
an adrenal with more than 1 nodule with CYP11B2 immunostaining
(Fig. 1). Cases of diffuse hyperplasia were excluded. Several adrenals
showed aldosterone-producing cell clusters which are defined as tight
clusters of cells with strong CYP11B2 immunostaining with zona glo-
merulosa morphology located beneath the capsule and extending into
the zona fasciculata [24,25]. The follow-up data of clinical and bio-
chemical parameters were obtained in the surgically treated patients at
6–12 months. Outcomes were defined as complete, partial and absent
clinical and biochemical success based on blood pressure measurements
and antihypertensive medication dosage for clinical outcomes or
plasma potassium and hormonal (aldosterone and renin) measurements
for biochemical outcomes [26].
2.3. Genotyping and gene expression analysis
Genomic DNA was extracted from frozen adrenal tissues and DNA
fragments of KCNJ5, ATP1A1, ATP2B3 and CACNA1D were amplified
by PCR using the primers shown in Table A.1, Supplementary data and
sequenced as described [27,28]. To our knowledge, PCR amplifications
using these primers potentially identify all somatic APA mutations in
the above genes described to date including the APA mutations de-
scribed in CACNA1D listed in Prada et al. [29], with the exception of
CACNA1D Glu412Asp, and the new CACNA1D mutation described re-
cently by Nanba et al. [30].
Total RNA was extracted from adrenal tissues (tumours and ad-
jacent cortex) and reverse transcribed as described previously [27].
Real-time PCR was performed in duplicate using TaqMan gene ex-
pression assays, and expression levels of CYP11B2 were analyzed by
2−ΔΔCt relative quantification using GAPDH as the endogenous re-
ference gene. All samples were included in the gene expression analysis
with available adenoma and corresponding adjacent cortical tissue (8
micro-APAs and 32 macro-APAs). CYP11B2 gene expression analysis
indicated an absence of CYP11B2 upregulation in 1 of the 8 samples
classified as micro-APAs (tumour-to-adjacent tissue CYP11B2 expres-
sion ratio= 0.934; genotype determined as wild type) and in 1 of 32
samples classified as macro-APAs (tumour-to-adjacent tissue CYP11B2
expression ratio= 0.926, genotype determined as wild type). This in-
dicates the missed dissection of the CYP11B2 positive nodule for the
micro-APA and the dissection of a nonfunctional adenoma as the largest
nodule for the sample classified as a macro-APA (Fig. A.1, Supple-
mentary data).
2.4. Immunohistochemistry and immunohistochemical characterization
Immunohistochemistry was performed on formalin-fixed, paraffin-
embedded tissue sections (3 μm) with an anti-CYP11B2 antibody (di-
lution 1:200, mouse monoclonal anti-human antibody, clone 17B, from
Dr Celso E. Gomez-Sanchez) [23] as described previously [31].
2.5. LC–MS/MS-based steroid profiling
Steroid profiling of peripheral venous plasma was done by LC–MS/
MS as described in full elsewhere [32] for the simultaneous measurement
of 15 steroids [aldosterone, 18-oxocortisol, 18-hydroxycortisol (18OH-
cortisol), 21-deoxycortisol, corticosterone, 11-deoxycorticosterone, pro-
gesterone, cortisol, cortisone, 11-deoxycortisol, 17-hydroxyprogesterone
(17-OH-progesterone), pregnenolone, androstenedione, dehydroepian-
drosterone (DHEA), and dehydroepiandrosterone sulphate (DHEAS)].
2.6. Statistical analyses
Quantitative normally distributed variables are expressed as means
with SDs and quantitative non-normally distributed variables are re-
ported as medians and interquartiles. Categorical variables are pre-
sented as absolute numbers and percentages. Comparisons between two
groups were assessed by a t test or a Mann-Whitney test; multiple
comparisons were assessed by ANOVA followed by Bonferroni test for
pairwise comparisons, or Kruskal-Wallis test with pairwise compar-
isons. Chi-square and Fisher’s exact-tests were used to compare cate-
gorical data. A logistic regression analysis identified steroids associated
with micro-APAs compared with macro-APAs and BAH with odds ratios
(OR) for steroids calculated per ng/mL. An OR greater than 1 indicates
an increased likelihood of micro-, macro-APAs or BAH, and an OR less
than 1 indicates a decreased likelihood. IBM SPSS Statistics version 25.0
were used for statistical analyses. P values are given to three decimal
places and are considered significant when P<0.05.
2.7. Predictive model
Random forest algorithms were performed using MATLAB R2017b
and PYTHON 2.7 to assess how concentrations of steroids in peripheral
venous plasma could be used to classify micro-, macro-APAs and BAH.
The prediction model can be used via an online tool which requires
operating system Windows version 64-bit or higher and is available at
https://github.com/ABurrello/Steroid-profiling-in-PA/archive/master.
zip.
3. Results
3.1. Patient characteristics, outcomes and immunohistochemical
characterization
Demographic and clinical characteristics at study entry and post-
operative follow-up of all patients are shown in Table A.2
(Supplementary data). There was an overall difference in this cohort in
the sex distribution of micro- and macro-APAs and BAH (P < 0.001)
with micro-APAs and BAH more prevalent in men than in women
(micro-APAs: 78.8% vs 21.2%; BAH: 73.9% vs 26.1%). Patients with
macro-APAs displayed the highest baseline concentrations of plasma
aldosterone (P < 0.001) and the lowest serum potassium concentra-
tions (P < 0.001) relative to the micro-APA or BAH group.
Micro-APAs displayed a lower prevalence of somatic KCNJ5 muta-
tions (3.2% vs 47.4%, P < 0.001) and a higher proportion of the wild-
type genotype (80.7% vs 36.2%, P < 0.001) compared with macro-
APAs.
Complete clinical and biochemical success were less frequent in the
micro-APA than in the macro-APA group (12.1% vs 40.0%, P=0.003,
84.8% vs 96.8%, P=0.023, respectively) whereas absent biochemical
success was more prevalent in the micro-APA group (9.1% vs 1.1%,
P=0.036). In total, 8 patients (5 with micro-APAs, 3 with macro-
APAs) displayed partial or absent biochemical success. CYP11B2 im-
munohistochemistry of these 8 resected adrenals demonstrated the
presence of a solitary functional macroadenoma in 3 samples. The re-
maining 5 adrenals comprised 1 with a solitary micro-APA and 4 which
did not have a solitary APA but showed more than one nodule with
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CYP11B2 immunostaining, with or without aldosterone-producing cell
clusters [25], with the larger nodule considered the micro-APA.
3.2. LC–MS/MS-based steroid profiling
LC–MS/MS-based steroid profiling of peripheral venous plasma re-
vealed some distinct differences between patients with micro-APAs,
macro-APAs and BAH (Fig. 2 and Table A.3, Supplementary data).
Patients with micro-APAs had lower peripheral plasma concentrations
of aldosterone (P=0.006), 18-oxocortisol (P < 0.001) and 18-hy-
droxycortisol (P < 0.001) compared with patients with macro-APAs.
The concentrations of the androgen precursor DHEAS were higher in
patients with micro-APAs versus those with macro-APAs (P=0.007).
There were no significant differences in single steroid concentrations
between patients with micro-APAs and BAH (Table A.3, Supplementary
data). Patients with macro-APAs displayed higher concentrations of
aldosterone, 18-oxocortisol, 18-hydroxycortisol (P<0.001) compared
with patients with BAH (Fig. 2 and Table A.3, Supplementary data).
Higher concentrations of 11-deoxycorticosterone and pregnenolone
(P=0.001 and P=0.006, respectively) and lower concentrations of
DHEA and DHEAS (P=0.010 and P=0.006, respectively) were mea-
sured in patients with macro-APAs relative to patients with BAH.
Potential associations of steroids with micro-APA, macro-APA and
BAH were determined by logistic regression models adjusting each
steroid separately for sex and age to avoid a reduction of the predictive
value of variables by collinearity (Table 1). Only steroids were entered
into the model which displayed a significant difference between sub-
type in the univariate analysis (Fig. 2, Table A.3, Supplementary data).
Age had no impact on diagnosis, whereas female sex was associated
with an increased likelihood of a diagnosis of a macro-APA compared
with a micro-APA and with BAH.
With the adjustment for sex and age, only lower concentrations of
18-hydroxycortisol were associated with an increased likelihood of a
micro-APA (OR 0.484 per ng/mL, 95% CI 0.289-0.812, P = 0.006).
Higher concentrations of 18-hydroxycortisol were associated with an
increased likelihood of a macro-APA versus BAH (OR 2.241 per ng/mL,
95% CI 1.458–3.444, P<0.001) (Table 1). Higher concentrations of
aldosterone, pregnenolone and 11-deoxycorticosterone were also as-
sociated with macro-APAs versus BAH (Table 1). In contrast, lower
concentrations of DHEA were associated with an increased likelihood of
a diagnosis of a macro-APA (OR 0.786 per ng/mL, 95% CI 0.656-0.941,
P = 0.009) (Table 1).
3.3. Random forest algorithm using steroid profiling
Random forest classification trees were used to build a prediction
model for micro-APAs, macro-APAs or BAH using peripheral plasma
steroid concentrations. The algorithm created 30 different classification
trees to optimize the prediction model and the predictive performance
of each steroid was estimated (Fig. 3A) and the first classification tree of
Fig. 2. Peripheral plasma steroid concentrations in patients with micro-APAs, macro-APAs and BAH.
The box and whisker plots (Panels A–G) represent peripheral plasma concentrations of the indicated steroids in patients with PA stratified for APA according to
tumor diameter (micro-APAs ≤10mm (n=33) and macro-APAs> 10mm (n=95)) and BAH (n= 69). Only steroids with significant differences in concentrations
between micro-APAs, macro-APAs and BAH are shown. Horizontal lines within boxes indicate the median, boxes and whiskers represent the 25th to 77th percentiles
and the minimum and maximum values, respectively, after exclusion of outliers that are defined by 1.5 times the interquartile range and are indicated by filled
circles. Concentrations are indicated in ng/mL which are converted to pmol/L by dividing by the molecular weight of each steroid: aldosterone, 360.44; 18-
oxocortisol, 376.45; 18-hydroxycortisol, 378.46; 11-deoxycorticosterone, 330.46; pregnenolone, 316.48; DHEA, 288.42; DHEAS, 367.50. P values were calculated
using Kruskal-Wallis tests followed by pairwise comparisons. 18OH-cortisol, 18-hydroxycortisol; APA, aldosterone-producing adenoma; BAH, bilateral adrenal
hyperplasia; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate.
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the forest is shown (Fig. 3B). AVS and pathology reports identified a
total of 33 micro-APAs, 11 of the 33 micro-APA were correctly classi-
fied by the random forest model (Fig. 3C). The correct classification of
macro-APAs was 96.8% (92 of 95, with 1 patient excluded as an
outlier), and 87.0% (60 of 69) of patients were correctly classified as
BAH (Fig. 3C). The overall accuracy of steroid profiling for the classi-
fication of the 3 groups (micro-APAs, macro-APAs and BAH) was 83.2%
(163/196), and the concordant diagnosis of APA and BAH between
Table 1
Peripheral plasma steroids associated with subtype diagnosis in primary aldosteronism.
Steroids (per ng/mL) OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Micro-APA vs. BAH (n=101*) Micro-APA vs. Macro-APA (n= 127*) Macro-APA vs. BAH (n=162*)
Age 0.992 (0.949–1.036) 0.713 0.969 (0.928–1.011) 0.148 1.021 (0.985–1.058) 0.253
Sex (ref: female) 0.674 (0.228–1.992) 0.476 0.209 (0.076–0.572) 0.002 3.015 (1.433–6.343) 0.004
Aldosterone 11.215 (0.682–184.508) 0.091 0.422 (0.045–3.969) 0.451 877.947 (23.235–33172.977) < 0.001
Age 0.995 (0.953–1.038) 0.813 0.966 (0.925–1.009) 0.116 1.022 (0.989–1.056) 0.201
Sex (ref: female) 0.808 (0.286–2.284) 0.687 0.197 (0.072–0.541) 0.002 3.271 (1.596–6.702) 0.001
18-Oxocortisol 1.291 (0.598–2.787) 0.515 0.761 (0.342–1.692) 0.503 2.984 (0.911–9.774) 0.071
Age 0.993 (0.951–1.037) 0.753 0.964 (0.920–1.010) 0.122 1.019 (0.985–1.055) 0.279
Sex (ref: female) 0.772 (0.275–2.171) 0.624 0.253 (0.087–0.738) 0.012 2.651 (1.241–5.662) 0.012
18-Hydroxycortisol 0.925 (0.528–1.623) 0.787 0.484 (0.289–0.812) 0.006 2.241 (1.458–3.444) < 0.001
Age 0.991 (0.949–1.035) 0.686 0.969 (0.928–1.011) 0.141 1.019 (0.986–1.054) 0.257
Sex (ref: female) 0.694 (0.236–2.040) 0.507 0.198 (0.073–0.542) 0.002 3.225 (1.562–6.658) 0.002
11-Deoxycorticosterone 8.194 (0.300–223.625) 0.212 0.807 (0.266–2.452) 0.705 137.637 (3.052–6207.424) 0.011
Age 0.994 (0.953–1.038) 0.790 0.961 (0.920–1.004) 0.077 1.024 (0.990–1.060) 0.165
Sex (ref: female) 0.794 (0.281–2.242) 0.664 0.198 (0.071–0.554) 0.002 3.363 (1.619–6.988) 0.001
Pregnenolone 1.062 (0.799–1.413) 0.677 0.743 (0.547–1.008) 0.057 1.486 (1.149–1.923) 0.003
Age 0.978 (0.933–1.025) 0.354 0.974 (0.930–1.021) 0.274 0.988 (0.950–1.027) 0.538
Sex (ref: female) 0.786 (0.276–2.238) 0.652 0.195 (0.071–0.532) 0.001 3.651 (1.768–7.540) < 0.001
DHEA 0.845 (0.673–1.060) 0.146 1.068 (0.868–1.315) 0.534 0.786 (0.656–0.941) 0.009
Age 0.988 (0.941–1.038) 0.641 0.983 (0.937–1.031) 0.477 0.995 (0.956–1.035) 0.793
Sex (ref: female) 0.720 (0.242–2.142) 0.555 0.245 (0.086–0.699) 0.009 2.646 (1.249–5.607) 0.011
DHEAS 1.000 (0.999–1.001) 0.658 1.001 (1.000–1.001) 0.182 0.999 (0.998–0.999) 0.048
Logistic regression analysis to identify adrenal steroids associated with micro-APAs, macro-APAs and BAH. An odds ratio greater than 1 indicates an increased
likelihood of micro-APAs compared with BAH or compared with macro-APAs or macro-APAs compared with BAH, and an odds ratio less than 1 indicates a decreased
likelihood. APA, aldosterone-producing adenoma; BAH, bilateral adrenal hyperplasia; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate;
OR, odds ratio. There were 33 patients in the micro-APA group; 94 in the macro-APA and 68 in the BAH groups. *1 patient from the BAH group was missing
pregnenolone data and was not included and 1 patient from the macro-APA group had outlier steroid profiling data.
Fig. 3. Peripheral venous steroid profiling for the classification of micro-APAs, macro-APAs and BAH.
The random forest algorithm constructed performance estimates for each steroid (Panel A), the first classification tree of the forest is shown for the prediction of
micro-APAs, macro-APAs and BAH (Panel B), and a table with the estimated classification by steroid profiling and the actual classification by AVS (to differentiate
BAH from APA) and pathology reports (to differentiate micro-APAs from macro-APAs) (Panel C). One patient had outlier steroid profiling results and was omitted.
Numbers indicate steroid concentrations in ng/mL. To convert concentrations in ng/mL to pmol/L, concentrations should be divided by the molecular weight of each
steroid. Molecular weights: 11-deoxycorticosterone, 330.46; 17-hydroxyprogesterone, 330.46; 18-hydroxycortisol, 378.46; 18-oxocortisol, 376.45; aldosterone,
360.44; corticosterone, 346.46; cortisol, 362.46. 17-OH-progesterone, 17-hydroxyprogesterone; 18OH-cortisol, 18-hydroxycortisol; APA, aldosterone-producing
adenoma; BAH, bilateral adrenal hyperplasia; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate.
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steroid profiling and AVS was 88.8% (174/196) (Fig. 3C).
3.4. Diagnostic algorithm combining steroid profiling, CT and AVS
An AVS-based approach was used for the therapeutic management
of the 197 patients in this study. Of these patients, 128 had laparoscopic
unilateral adrenalectomy for resection of an APA and 69 were treated
with MRAs for BAH (Fig. 4A). For the surgically-treated patients, 93.7%
(120 of 128) displayed complete biochemical success after surgery. In
patients with complete biochemical success, pathology reports in-
dicated that the prevalence of micro-APAs was 23.3% (28 of 120 pa-
tients) and of macro-APAs 76.7% (92 of 120 patients). The remaining
6.3% (8 of 128 patients) displayed biochemical evidence of persistent
hyperaldosteronism (partial or absent biochemical success). Assuming
the patients with partial or absent biochemical success represent pa-
tients with a presurgical misdiagnosis of unilateral PA instead of bi-
lateral PA, and the diagnosis of BAH with non-lateralized aldosterone
secretion was accurate in all cases, the diagnostic accuracy of AVS-
based management in the study cohort was 95.9% (189 of 197)
(Fig. 4B).
We tested the performance of a diagnostic algorithm using periph-
eral venous steroid profiling and CT scanning in all patients and AVS
limited to patients with discordant steroid profiling and CT scanning
results (Fig. 4C). Applying this algorithm to the same cohort (n=197
patients), peripheral venous steroid profiling would have predicted 11
patients with micro-APAs, 112 patients with macro-APAs and 73 pa-
tients with BAH. Of these patients, the 11 micro-APAs were correctly
classified, 11 patients with micro-APAs were misclassified as macro-
APAs, and 9 patients with BAH were incorrectly classified as macro-
APAs. These 31 patients would be addressed to AVS for subtype dif-
ferentiation because of potential discordant steroid profiling and CT
scanning results.
An additional 2 of the 73 patients misclassified as BAH from steroid
profiling instead of macro-APA would potentially be selected for AVS
because of the detection of a unilateral adenoma at imaging. The pa-
tient with a macro-APA, classified as an outlier by steroid profiling,
would also have been addressed to AVS. Therefore, a total of 34 pa-
tients would have AVS potentially resulting in, at the most, a theoretical
reduction of AVS procedures by 82.7% (163 of 197 patients would
bypass AVS assuming a normal CT morphology of the contralateral
gland) with a comparable accuracy of diagnosis (92.4%) (Fig. 4D) to
that of AVS-based management. The accuracy for the correct classifi-
cation of micro-APAs could have reached 67.9% (19 of 28, 5 patients
were excluded from the micro-APA group because they were not bio-
chemically cured after adrenalectomy resulting in 28 patients with
unilateral micro-APA), and the number of patients with incomplete
biochemical cure after surgery (absent or partial biochemical success)
would have decreased from 8 with the AVS algorithm (Fig. 4B) to 6
(5.1%) with the diagnostic algorithm incorporating steroid profiling
(Fig. 4D). Eleven patients with micro-APAs would have been diagnosed
Fig. 4. Clinical management algorithms for patients with primary aldosteronism.
The AVS-based management of patients in this study is shown (Panel A), and results in the accurate differentiation of APA from BAH in at best 95.9% of patients
(assuming a correct diagnosis of all patients with BAH) (Panel B). The diagnostic accuracy of APA is assessed here by the proportion of patients with biochemical
cure (120 of 128 patients with complete biochemical success). No biochemical cure was observed in 6.3% (8 of 128 patients with absent or partial biochemical
success). Therapeutic management based on peripheral venous steroid profiling and CT scanning with AVS in a restricted subset of patients (patients with discordant
CT and steroid profiling results) would have reduced AVS procedures by at most 82.7% (34 of 197 patients addressed to AVS) and potentially 92.4% of patients would
have had an accurate differentiation of APA from BAH (Panel C). The patient with outlier steroid profiling results would have been addressed to AVS. The number of
patients with an absent or partial biochemical outcome would have been reduced to 6 (5.1%, 6 of 117) (Panel D). Numbers in bold indicate numbers of patients.
APA, aldosterone-producing adenoma; AVS, adrenal venous sampling; CT, computed tomography; MRA, mineralocorticoid receptor antagonist; PA, primary al-
dosteronism.
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with BAH of which 9 were micro-APAs (from patients with complete
biochemical success after surgery) and the remaining 2 patients (with
absent or partial biochemical success) would have received the correct
treatment with a MRA (Fig. 4D).
4. Discussion
We measured peripheral plasma steroid profiles by LC–MS/MS in a
large series of patients with PA and determined the potential utility of
integrating these measurements in therapeutic management. We fo-
cussed on using this approach to identify patients with micro-APAs
which are often missed by CT in those centres that rely on CT for the
differentiation of APA from BAH. The similar steroid profiles of patients
with micro-APAs and BAH limits the application of a method based on
steroid measurements alone but when considered in a diagnostic work
up that includes interpretation of CT results and AVS (restricted to
patients with discordant steroid profiles and CT data), the theoretical
algorithm performed almost as well as AVS alone for the diagnosis of
micro-APAs.
We also analysed the post-surgical clinical and biochemical out-
comes of all patients with a unilateral APA (n = 128) included in the
study in accordance with the PASO consensus, a standarized set of
criteria to define outcomes of adrenalectomy for unilateral PA [26]. A
smaller proportion of patients with micro-APAs achieved complete
clinical and biochemical success than patients with macro-APAs but this
is likely mainly due to the sex distribution difference between patients
with micro-APAs (comprising a higher proportion of males and patients
with a higher BMI) and with macro-APAs [26]. The sex distribution of
our cohort may partially explain the difference between our findings
and those of Omura et al., who reported an increase in the proportion of
patients achieving clinical cure after surgical removal of micro-APAs (n
= 27) compared with macro-APAs (n = 42) [18]. Although larger
nodule size was associated with complete clinical success after adre-
nalectomy in a multicohort study [25] and APAs with KCNJ5 muta-
tions, which tend to be larger than other APAs [32,33], are also asso-
ciated with favourable outcomes post-surgery [34].
Patients with absent or partial biochemical success after surgery
were predominantly in the micro-APA group. CYP11B2 im-
munohistochemistry of the resected adrenals showed that they mostly
comprised more than one micronodule with positive CYP11B2 im-
munostaining, in agreement with the suggestion that CYP11B2 im-
munohistochemistry of resected adrenals may be useful as an indicator
of biochemical outcomes and highlight patients which require ongoing
follow-up with biochemical as well as clinical re-assessment [31]. De-
spite the over-representation of micro-APAs in the group of patients
who were not biochemically cured after adrenalectomy, this none-
theless comprised only 15% (5 of 33) of patients with micro-APAs in-
dicating that it is worthwhile and potentially rewarding for patients to
have further work up for the identification of micro-APAs.
The small area of the resected adrenal with CYP11B2 im-
munostaining in micro-APAs likely explains the decreased presurgical
plasma aldosterone concentrations of the corresponding patients com-
pared with those with macro-APAs as suggested by a previous report
[21]. Patients with micro-APAs also had lower plasma concentrations of
the hybrid steroids, 18-oxocortisol and 18-hydroxycortisol, relative to
the macro-APA group but comparable to patients with BAH. This is
feasibly explained by the larger size of APA carrying KCNJ5 mutations
[35,36] and the association of KCNJ5-mutated APAs with an increased
production of 18-oxocortisol and 18-hydroxycortisol [11]. In line with
this, we show that the micro-APA group displayed a lower prevalence of
KCNJ5 mutations compared with the macro-APA group. Further, a lo-
gistic regression model with adjustment of each steroid concentration
for sex and age, showed an association of higher 18-hydroxycortisol
concentrations (but not 18-oxocortisol) with an increased likelihood of
a diagnosis of a macro-APA compared with micro-APA and with BAH.
The association of female sex with macro-APAs and with increasing
plasma aldosterone concentrations is consistent with a meta-analysis
report of patients with KCNJ5-mutated APAs displaying larger tumours
and more pronounced hyperaldosteronism compared with patients with
APAs without KCNJ5 mutations [36].
Larger APAs may have increased glucocorticoid co-secretion
[37,38] which would be expected to suppress pituitary ACTH produc-
tion. ACTH is the main regulator of the synthesis of DHEA and DHEAS
and therefore increased glucocorticoid co-secretion from macro-APAs
may partly explain the lower concentrations of these steroids observed
in patients with macro-APAs compared with patients with micro-APAs
and BAH. Additional studies are required to address the role of APA size
and genotype on glucocorticoid co-secretion with the inclusion of
plasma ACTH measurements to establish their effects on the steroid
profile.
In the PASO study, 6% of 699 patients did not display complete
biochemical cure after adrenalectomy for APA and this group comprises
cases of PA with bilateral asymmetrical aldosterone excess with a po-
tential misdiagnosis of unilateral PA [26]. This compares favorably
with CT based decision making for adrenalectomy, where 20% of pa-
tients with APA are not biochemically cured [39,40]. Using AVS results
as the reference standard, the correct diagnosis of unilateral and bi-
lateral PA by adrenal imaging (CT or magnetic resonance) was reported
as 62.2% [41]. In another study on patients with unilateral APA (di-
agnosed by AVS) with follow-up data, 36% of patients who were bio-
chemically cured after adrenalectomy would have been misdiagnosed
on the basis of CT results [40]. Thus, neither CT nor AVS are completely
reliable and strong interest focusses on approaches to improve the
performance and accessibility of subtype differentiation in PA [12–17].
The potential utility of adrenal steroids in discriminating different
subtypes of PA has been investigated in numerous studies with atten-
tion centering on the hybrid steroids 18-oxocortisol and 18-hydro-
xycortisol in urine or plasma [42]. Peripheral plasma 18-oxocortisol
concentrations measured by LCeMS/MS can distinguish CT-detectable
APA and BAH in patients from Japan [43]. However, in a European
cohort, this method appears to be unreliable whereas a panel of 12
adrenal steroids in peripheral plasma differentiated APA from BAH with
an accuracy of 80% [13]. The higher production of 18-oxocortisol in
patients with KCNJ5-mutated APAs may explain the increased perfor-
mance of 18-oxocortisol for differentiating APA from BAH in those
cohorts with higher prevalences of KCNJ5 mutations (as in Japan)
compared with other populations (as in Europe) [13,43].
Genotype data in this study, as in most preceeding studies, should
be interpreted with caution because recent evidence shows that when
sequencing is targeted to areas of the adenoma that are positive for
CYP11B2 expression, somatic mutations are detected in almost 90% of
APAs [30]. Therefore, the non-targeted sequencing approach used here
is a limitation of the current study with an overrepresentation of the
“wild-type” genotype notably in the micro-APA group because tissue
dissection may have missed the micronodule. Further, the macro-APA
group was not defined by CYP11B2 immunohistochemistry but by pa-
thology reports of the largest nodule size (which would have been the
nodule sampled for sequencing) and may comprise CYP11B2-negative
nodules with a wild-type genotype [33]. In these cases, a secondary
nodule (or multiple APCCs) responsible for the pathologic aldosterone
production [34,44] would not have been sequenced. We showed by
CYP11B2 gene expression analysis of samples classified as adenomas
compared with paired adjacent adrenal cortical tissue that the above
occured but in a minority of cases.
In the present study, patients with micro-APAs could not be pre-
dicted by steroid profiling alone. This was expected considering the
high similarity we show of steroid profiles in patients with micro-APAs
and BAH. To improve the reliability of identifying micro-APAs, we
developed a hypothetical diagnostic algorithm integrating the addi-
tional consideration of CT imaging and using AVS only in patients with
discordant steroid profiles and imaging data. The algorithm increased
the probability of identifying micro-APAs whilst reducing the
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proportion of AVS procedures by up to 82.7% but achieving a com-
parable accuracy of diagnosis with AVS-based management.
The strengths of our study are the large patient cohort with strict
inclusion criteria for screening, diagnosis and subtype differentiation
from 2 expert centres that use similar AVS protocols [10,22]. All pa-
tients had peripheral venous steroid measurements by LCeMS/MS and
assessment of post-surgical clinical and biochemical outcomes in sur-
gically-treated patients using the international PASO consensus. Further
strengths are the development of an accessible online tool for the pre-
diction of microAPA, macroAPA and BAH. Limitations of our study are
the non-targeted genotyping approach and the potential inclusion of
nonfunctional adenomas in the macro-APA group as discussed above
and the relatively small number of patients with micro-APAs compared
with macro-APAs and BAH. An additional limitation is the assumption
of a correct detection of macro-APAs by CT scanning in the theoretical
diagnostic algorithm.
5. Perspectives
Steroid profiling of peripheral venous plasma could potentially be
used in combination with imaging data and AVS restricted to a small
proportion of patients to identify patients in whom AVS should be
considered mandatory. Such an approach may be useful in centres that
rely on CT for subtype differentiation in PA because such approaches
can lack the required sensitivity to detect micro-APAs.
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